Session » Biology and Pathology of Bone and Joint (Bone and Arthritis)

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1822

Oleanolic Acid Acetate Inhibits Osteoclast Differentiation By Downregulating Phospholipase Cγ² –calcium ion oscillation-Nuclear Factor Of Activated T Cell c1 Signaling, and Suppresses Bone Loss In Mice

Abstract Number: 1823

IL-6 Suppresses Osteoblast Differentiation Through The SHP2/MEK2 and SHP2/Akt2 Pathways In Vitro

Abstract Number: 1824

ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation

Abstract Number: 1825

Osteoclast Progenitors, Fibroblast-Like Cells and Draining Lymph Node Cells Induce Catecholaminergic-To-Cholinergic Transition Of Sympathetic Nerve Fibers Under Healthy Conditions But Not In Highly Inflamed Arthritic Tissue

Abstract Number: 1826

Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding

Abstract Number: 1827

The Intraarticular Injection Of An Inhibitor Of Complex V Of Mitochondrial Respiratory Chain Induces a Pathological Response In Rat Knee Joints

Abstract Number: 1828

In Vivo Cartilage-Specific Deletion Of Ephrin-B2 In Mice Results In Developmental Locomotory Defects Associated With Hip Bone Abnormality

Abstract Number: 1829

Carboxypeptidase B2 Down-Regulates Osteoclast Activation In Inflammation

Abstract Number: 1830

Adenosine A_2A Receptor (A2AR) Diminishes Wear Particle (UHMWPE)-Mediated Osteolysis, Increases Bone Formation and Regulates Expression Of Axonal Guidance Proteins (AGP) By Macrophages, Osteoclasts (OC) and Osteoblasts (OB)

Abstract Number: 1831

Study Of Serum Levels Of Osteocalcin (s-OC) On Patients With Diffuse Idiopathic Skeletal Hyperostosis (DISH) and Ankylosing Spondilitis (AS)

Abstract Number: 1832

Discovery of MicroRNAs in the Regulation of Inflammation and Bone Erosion in Rheumatoid Arthritis

Abstract Number: 1833

Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo

Abstract Number: 1834

Abnormal Collagen Fibers Deposition In The Synovial Joints Is a Characteristic Of The Temporal Evolution Of The Diabetic rats’ Model Induced By Streptozotocin

Abstract Number: 1835

Dynamic Visualization Of Monocyte Migration In 3D Synovial Micromass Tissue Cultures

Abstract Number: 1836

Suppression Of HDAC5 Expression By Inflammatory Cytokines Is Required To Promote CXCL Chemokine Production In RA FLS

Abstract Number: 1837

Three-Dimension Culture Of Mesenchymal Stem Cells With Nano-Fiber Scaffold Induces Chondrogenesis and Osteogenesis

Abstract Number: 1838

The Use Of Three-Dimensionally Printed β-Tricalcium Phosphate/Hydroxyapatite To Understand The Regulation Of Adenosine Receptors In Osteoclast Formation and Promotion In Bone Regeneration

Abstract Number: 1839

Osteoclastogenesis Is Enhanced By Synovial Fluid Derived Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.